Superbugs: Exclusive Interviews Released with ABAC Therapeutics, Alchemy Biomedical and Oppilotech

Superbugs & Superdrugs 2018

Superbugs & Superdrugs 2018

SMI REPORTS: Expert insight into tackling the scientific, regulatory and economic challenges to combat antimicrobial resistance.

The conference is focused and includes all relevant topics related to the discovery of new antimicrobial agents.”

— ABAC Therapeutics

LONDON, ENGLAND, UNITED KINGDOM, November 22, 2017 /EINPresswire.com/ — It is imperative for medical experts and drug discovery specialists to stay on top of the latest clinical advancements, developments and industry initiatives related to antimicrobial resistance. For this reason, SMi Group have gathered industry experts and government bodies to share their insights at the 20th annual conference on Superbugs and Superdrugs taking place on 19th and 20th March in London, UK.

SMi Group had the opportunity to sit down with three of the featured speakers to discuss some of the challenges they face in the industry and their strategies for overcoming them. The full interviews are available to read in the event download center.

"The fight against multi-resistant organisms requires the implementation of several measures coordinated at a global level. The rational use of antibiotics is an important challenge that we have to improve. Although, the biggest challenge is the discovery of new antibacterial agents with a novel mechanism of action, that allows us to increase the therapeutic arsenal against organisms that are practically lacking therapeutic alternatives" said Domingo Gargallo-Viola, Chief Scientific Officer from ABAC Therapeutics. "To discover new antibiotics, we have to be visionaries, we have to end with the unproductive nightmare of the last 50 years, for which we have to define new TPPs and improve the productivity of discovery processes, applying disruptive strategies to reduce the failure rate, and therefore the high technical risk associated with the area of infectious diseases."

When asked Oppilotech’s 'cell envelope model', a novel platform being utilised to discover and develop an internal pipeline of new antibacterial drugs, John George, Founder and Chief Scientific Officer from Oppilotech said “An accurate model allows us to identify nodes within the network which when inhibited, would weaken the outer membrane. The more permeable membrane would now allow compounds such as rifampin, erythromycin and kanamycin into the cell. This will impact AMR in a number of ways, firstly, it would allow these well established drugs to be used for the treatment of gram negatives. Secondly, because of the weakened membrane the intracellular concentration of drug would be much higher than normal, minimising the risk of low level resistance. Finally, the active agents could be given a lower dose which would reduce any associated toxicities."

On harnessing a patient's immune system to combat drug resistant bacteria, David Brown, Managing Director and Founder of Alchemy Biomedical Consulting said, “Our immune system is protecting us every second of the day from attack by infectious micro-organisms. It is immensely powerful, far more so than any antibiotic. So, I believe that immune modulation will be far more powerful in beating antibiotic resistance that just inventing more antibiotics or using combinations of antibiotics. Yet there is little research in this area. Bacteria invade by usurping our immune system. Research in the last few years has identified the mechanisms bacteria use to achieve this, but that knowledge has not been picked up by the antibiotic / microbiology community. I want to begin the process of getting it into the mainstream via this conference."

SMi’s 20th Annual conference on Superbugs & Superdrugs will take place on 19th & 20th March 2018 at the Copthorne Tara Hotel, Kensington in London, UK.

Further details including a full speaker line-up and detailed programme are available at www.superbugssuperdrugs.com

— end —

Contact Information:

For all media enquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: tarri@smi-online.co.uk
For exhibition and sponsorship enquires contact Alia Malick on Tel: +44 (0)20 7827 6168 / Email: amalick@smi-online.co.uk

About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Teri Arri
SMi Group
2078276000
email us here


Source: EIN Presswire

Virtual Reality Education Booming in Middle East

Unity Technologies along with Munfarid Consulting, have been winning the attention at EdEx conference with the unique offering of providing Virtual Reality aided learning solutions in education.”

— EdEx MENA

DUBAI, UNITED ARAB EMIRATES, November 22, 2017 /EINPresswire.com/ — The all-important EdEx MENA conference has been going strong in Dubai, drawing the entire private education community from all over Middle East. A large number of educators, institutional heads and edtech solution providers have gathered for the event.

EdEx MENA is essentially focused at improving the quality of higher education and building a bridge between today’s resources and future opportunities. The idea is to elevate the level of private education to a level where it not only competes globally but also helps shape the competencies of the youth for the requirements and challenges of the changing world.

Once again, the region’s leading company for Augmented & Virtual Reality – Munfarid Consulting – from the Kingdom of Bahrain was the spark of the show, the company is leading innovation in education, corporate and industrial sectors through immersive technologies in the Middle East. Munfarid was joined with Unity Technologies, a world-class name in the technology driven community, and stands at the forefront of the growing VR market with a strong focus on the development of robust software solutions.

Unity Technologies along with Munfarid Consulting, have been winning the attention at EdEx conference with the unique offering of providing Virtual Reality aided learning solutions in education. The idea that the immersive VR technology can rapidly adapt to the demands of the expeditious “technological era”, has definitely sunk in for the educational community. The VR learning solutions not only provide deeper information and sound understanding in less amount of time, they also make it possible to educate students thoroughly about various disciplines in a safe, virtual environment such as geography, archeology, chemistry, medical studies and many more.

This is the first time for Unity Technologies team to have come to UAE to participate in an educational event with the intent to expand their operations in the Middle East.
Dr. Abdullah al Karam, Director General Knowledge and Human Development Authority (KHDA), experienced the VR technology and appreciated the efforts of Munfarid VRXOne in bringing innovating ways of delivering education in classrooms to the Middle East. Dr. Abdullah’s positive response is a source of great appreciation for Munfarid team as the KHDA itself is a dedicated government consultancy authority responsible for the growth and quality of private education in Dubai, supporting universities, parents, students, educators, investors and government partners to create a high quality education sector focused on happiness and wellbeing.

Hajra Khan
Munfarid Consulting Co. SPC.
+97366656613
email us here


Source: EIN Presswire

Agenda released for SMi Group’s Controlled Release Delivery 2018

Controlled Release Delivery 2018

Controlled Release Delivery 2018

LONDON, ENGLAND, UNITED KINGDOM, November 22, 2017 /EINPresswire.com/ — Building on the success of previous events, SMi has announced the return of its 15th annual Controlled Release Delivery, taking place on 21st and 22nd March in London, UK.

An industry-leading show, the conference has been running for 15 years – a testament of how vital this particular focus is to the biotech and pharma sector. As physicians and scientists continue to find strategies to assist in simplifying treatment schedules for patients, a pharma focus continues to move towards innovative controlled release technologies to improve drug transport to target.

Moreover, with the global oral controlled release drug delivery technology market expected to flourish in the next 10 years, the conference aims to explore and to understand innovations in oral-lipid based and abuse deterrent formulations, nanoparticles and nanotechnologies, taste-masking and controlled release approaches, 3D printed dosage forms and functional film coats.

Event highlights will include sessions on

• formulation of Controlled Release Delivery Technologies and improving the design of new controlled release delivery systems;
• innovative additions to Oral Controlled Release Delivery Technologies, to improve the pharmacokinetic-pharmacodynamic properties of the drug;
• latest regulation guidance and their implications for the pharmaceutical industry; and
• clinical developments and lessons learnt during clinical trials, through case studies with top pharmaceutical companies.

Featured speakers include:
• Howard Stevens, Emeritus Professor, University of Strathclyde
• Joël Richard, Senior Vice President, Peptides Development, Ipsen
• Mohamed Albed Alhnan, Senior Lecturer, University of Central Lancashire
• Pavel Farkas, Senior Director – Biopharmaceutics/ Clinical Development, PLIVA
• Barry Friend, Sr. Technical Manager, Colorcon
• Sebastian Schwier, Project Director / Int. Technical Project Leader, ‎Grünenthal
• Karsten Lindhardt, CSO, Head R&D, Egalet
• Teofilo Vasconcelos, Formulation Manager, Bial
• Guillaume Saint-Pierre, Chief Executive Officer and Cofounder, PeptiGelDesign

…and more. The full roster of speakers can be found on www.controlledreleasedelivery.com/ein.

For those interested to attend, registration is now live on the event website and there is currently an Early Bird Discount of £400 which expires on 30 November 2017.

15th Controlled Release Delivery Conference
21-22 March 2018
Copthorne Tara Hotel, London, UK

— END —
For delegate registration enquiries, contact Kieran Ronaldson on kronaldson@smi-online.co.uk. For media enquiries, contact Honey de Gracia at hdegracia@smi-online.co.uk.
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Honey de Gracia
SMi Group Ltd
+44 (0)20 7827 6102
email us here


Source: EIN Presswire

Healthcare, Regulatory and Reimbursement Canada Market Analysis 2017 and Forecasts To 2022

Healthcare, Regulatory and Reimbursement Canada Market 2017 Share, Trend, Segmentation and Forecast to 2022

PUNE, INDIA, November 22, 2017 /EINPresswire.com/ — Pune, India, 22nd November 2017: WiseGuyReports announced addition of new report, titled “CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Canada”.

Summary
The industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Canada". The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in Canada. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of Canada. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house analysis by team of industry experts.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/1705960-countryfocus-healthcare-regulatory-and-reimbursement-landscape-canada

In 2016, Canada population was approximately at 36.3 million. The Canadian pharmaceutical industry is the 10th largest market with a share of 2% of the global market. In 2015, pharmaceutical sales were estimated at $22.1 billion. This rose to about $22.6 billion in 2016 and is forecast to increase to $25 billion in 2021, at a CAGR of 2%. Patented drugs accounted for 61.8% of the total sales in 2015. The medical device market in Canada was worth $8.7 billion in 2009, which increased to $11 billion in 2016. It is expected to grow at a CAGR of 4.2% from $11.5 billion in 2017 to $13.5 billion in 2021. The main segments ophthalmic devices, orthopedic devices, drug delivery devices, in vitro diagnostics and healthcare IT will drive market growth.

These positive trends can primarily be attributed to –
– Increasing awareness regarding early disease detection and diagnosis
– Advances in medical technology

Scope
The report provides information on the healthcare, regulatory, and reimbursement landscape in Canada, and includes –
– An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers
– Profiles and SWOT analyses of the major players in the pharmaceutical market (Johnson & Johnson, Novartis, Teva, Apotex and Gilead) and profiles and SWOT analyses of the major players in the medical device market (Johnson & Johnson, Medtronic, Baxter, Fresenius and Sonova)
– An insightful review of the reimbursement and regulatory landscape, of which analysis includes details of the healthcare reimbursement process, the regulatory agencies and the approval processes for new drugs and medical devices
– Detailed analysis of the political and economic environment, covering economic indicators, demographics, healthcare infrastructure and healthcare expenditure
– An overview of the opportunities for and challenges to growth in the Canadian healthcare market

Reasons to buy
This report will enhance your decision-making capability by allowing you to –
– Develop business strategies by understanding the trends shaping and driving the Canadian healthcare market
– Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments, and companies likely to impact the healthcare market in the future
– Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors
– Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment, and strategic partnership
– Identify, understand, and capitalize on the opportunities and challenges in the Canadian healthcare market

Table of Content: Key Points

1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 7
2 Executive Summary 9
3 Introduction 14
3.1 GlobalData Report Guidance 14
4 Overview of the Pharmaceutical and Medical Device Markets 15
4.1 Pharmaceutical Market 15
4.1.1 Market Overview 15
4.1.2 Pharmaceutical Imports and Exports 19
4.1.3 Supply Channels 20
4.1.4 Market Segments 21
4.1.5 Overview of Major Therapeutic Areas 25
4.1.6 Overview of Major Drug Classes 27
4.1.7 Major Players 29
4.2 Medical Device Market 62
4.2.1 Market Overview 62
4.2.2 Overview of Top Five Segments 65
4.2.3 Major Players 76
4.3 Market Drivers and Barriers 101
4.3.1 Drivers 101
4.3.2 Barriers 102
5 Market Access 104
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/1705960-countryfocus-healthcare-regulatory-and-reimbursement-landscape-canada

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Type 2 Diabetes Therapeutic and Drug Pipeline Review 2026

Global Type 2 Diabetes Drugs and Companies Pipeline Review 2017-2026

PUNE, INDIA, November 22, 2017 /EINPresswire.com/ — Summary
While the global T2D market is crowded with inexpensive generics and marked by a pipeline filled with me-too drugs, expects this market to undergo substantial growth between 2016 and 2026, doubling over the forecast period. The main driver of this enormous expansion will be the dramatic increase in disease prevalence, which is attributable to increased life expectancy and an increasingly sedentary and stressful lifestyle. The second largest driver will be physicians’ efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded drugs.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/2401034-pharmapoint-type-2-diabetes-global-drug-forecast-and-market-analysis-to-2026

Despite the large number of marketed therapies, the T2D market is still experiencing large unmet needs and therefore has a significant growth opportunity for new patent-protected products. Metformin (dimethylbiguanide) will remain the first-line therapy overall for T2D due to physicians’ familiarity with it and the availability of long-term data, but the usage of sulfonylureas (SUs), another front-line therapy, continues to be replaced by novel therapies with improved side-effect profiles. The battle for second- or third-line therapy will involve DPP-4Is, GLP-1RAs, SGLT-Is, and other upcoming novel therapies. Of all the currently marketed classes, GLP-1RAs and SGLT-Is will experience the fastest growth due to their beneficial CV effects, weight-loss effects, and increasing ease of use.

Scope
– Overview of T2D, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
– Annualized T2D therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2016 and forecast for ten years to 2026.
– Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the T2D therapeutics market.
– Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
– Analysis of the current and future market competition in the global T2D therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy
The report will enable you to –
– Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
– Develop business strategies by understanding the trends shaping and driving the global T2D therapeutics market.
– Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global T2D therapeutics market in future.
– Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
– Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
– Track drug sales in the global T2D therapeutics market from 2016-2026.
– Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Content: Key Points
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 10
2 Type 2 Diabetes (T2D): Executive Summary 11
2.1 T2D Sales to Double Across 7MM 12
2.2 Multiple Opportunities Exist to Address Existing T2D Market Unmet Needs 14
2.3 The Arrival of Insulin Biosimilars and Abundance of “Me-Too” Drugs Illustrates Corporate Shift in Focus from Therapeutic Value Towards Competitive Pricing and Non-novel Agents that Confer Incremental Benefits 18
2.4 Glucagon-Like Peptide -1 Receptor Agonist Class Faces Intense Internal Competition, Largely Revolving Around Drugs’ Ability to Improve Patient Compliance/Ease of Administration and Cardiovascular Effects 19
2.5 Newest T2D Drug Class, Sodium-Glucose Cotransporter Inhibitors, Will Continue To Gain Significant Market Share Despite Concerns 19
2.6 What Do Physicians Think? 20
3 Introduction 23
3.1 Catalyst 23
3.2 Related Reports 24
4 Disease Overview 25
4.1 Etiology 25
4.2 Pathophysiology 27
4.3 Symptoms 29
4.4 Prognosis 31
4.5 Quality of Life 31
5 Epidemiology 31
5.1 Disease Background 32
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/2401034-pharmapoint-type-2-diabetes-global-drug-forecast-and-market-analysis-to-2026

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Minimally Invasive Spine – Current and Future Players

Minimally Invasive Spine Therapeutics Development and Professional Review Analysis 2017

PUNE, INDIA, November 22, 2017 /EINPresswire.com/ — Summary
Traditionally treated with an open surgical approach to stabilize vertebral bones and joints, spinal fusion is one of a number of surgical procedures that has begun the shift towards less invasive surgical techniques. With the advent of advanced imaging technologies, minimally invasive techniques have emerged as a solution to many of the disadvantages of traditional spinal fusion. Shorter operation time, less trauma to the patient’s anatomy, and faster return to motion are benefits of minimally invasive spine (MIS) surgery that, coupled with the global aging population and continued advancements in navigational technology, will propel its adoption. However, the growth of motion preserving solutions, cost-containment pressures in European healthcare systems, and low physician and patient awareness in emerging markets threaten the widespread adoption of this approach.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/1201849-minimally-invasive-spine-current-and-future-players

This report provides up-to-date information and in-depth analysis on the key players that shape the global MIS market. This includes an analysis of company profiles, industry trends, and corporate strategy. The report identifies the unmet needs in the market while providing an understanding of physicians’ perceptions and decision-making processes in using and evaluating the adoption of different types of devices.

Scope
– Investigation of current and future market competition in the MIS market.
– Competitive Assessment including product profiles.
– Coverage of key market players and company profiles, including business description, financial overview, product portfolio assessment, and SWOT analysis.
– Strategic Assessment of the market through market impact analysis, future market scenario, and company analysis.

Reasons to buy
– Gain a high level view of the trends shaping and driving the MIS market.
– Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
– Drive revenues, formulate effective sales and marketing strategies, and gain in-depth understanding of the competitive landscape.
– Take a comprehensive look at the market’s device pipeline and identify promising, paradigm-shifting products.
– Create an effective counter-strategy to gain a competitive advantage against those currently in the market.

Table of Content: Key Points
1 Table of Contents 1
1.1 List of Tables 4
1.2 List of Figures 5
2 Introduction 11
2.1 Catalyst 11
2.2 Related Reports 11
3 Competitive Assessment 26
3.1 Market Share Analysis 26
3.1.1 Global Overview 26
3.1.2 North America 27
3.1.3 Europe 28
3.1.4 Asia-Pacific 29
3.1.5 South America 30
3.1.6 Middle East and Africa 31
3.2 Key Companies and Product Profiles 32
3.2.1 DePuy Synthes (JNJ) 32
3.2.2 Globus Medical 34
3.2.3 Medtronic 35
3.2.4 NuVasive 36
3.2.5 Stryker 38
3.2.6 Zimmer Biomet 39
3.2.7 Other Players 41
3.3 Clinical Trials to Watch 44
3.4 Pipeline Products Assessment 46
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/1201849-minimally-invasive-spine-current-and-future-players

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Tissue Engineered Market 2017 EU5 Analysis, Opportunities and Forecast to 2022

Tissue Engineered Industry EU5 Market Trends, Share, Size and 2022 Forecast Report

PUNE, INDIA, November 22, 2017 /EINPresswire.com/ — Pune, India, 22nd November 2017: WiseGuyReports announced addition of new report, titled “EU5 Tissue Engineered – Skin Substitute Procedures Outlook to 2024”.

Summary
EU5 Tissue Engineered – Skin Substitute Procedures Outlook to 2024, provides key procedures data on the EU5 Tissue Engineered – Skin Substitute Procedures. The report provides procedure volumes within market segments – Biologic Skin Substitute Procedures, Synthetic Skin Substitute Procedures and Biosynthetic Skin Substitute Procedures.

The data in the report is derived from dynamic market forecast models. uses epidemiology based models to estimate and forecast the procedure volumes. The objective is to provide information that represents the most up-to-date data of the industry possible.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/2479018-eu5-tissue-engineered-skin-substitute-procedures-outlook-to-2024

The epidemiology-based forecasting model makes use of epidemiology data gathered from research publications and primary interviews with physicians to establish the target patient population and treatment flow patterns for individual diseases and therapies. Using prevalence and incidence data and diagnosed and treated population, the epidemiology-based forecasting model arrives at the final numbers.

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the procedure volumes.

Scope
– EU5 Tissue Engineered – Skin Substitute Procedures volumes by segments – Biologic Skin Substitute Procedures, Synthetic Skin Substitute Procedures and Biosynthetic Skin Substitute Procedures.
– Projections for each of the market segments. Data is provided from 2010 to 2017 and forecast to 2024.

Reasons to buy
– Develop business and investment strategies by identifying the key market segments expected to register strong growth in the near future.
– Develop market-entry and market expansion strategies.

Table of Content: Key Points
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Introduction 4
2.1 What Is This Report About? 4
2.2 Tissue Engineered – Skin Substitute Procedures, Segmentation 4
2.3 Definitions of Procedures Covered in the Report 5
3 Tissue Engineered – Skin Substitute Procedures, EU5 6
3.1 Tissue Engineered – Skin Substitute Procedures, EU5, 2010-2024 6
3.2 Tissue Engineered – Skin Substitute Procedures, EU5, 2010-2017 7
3.3 Tissue Engineered – Skin Substitute Procedures, EU5, 2017-2024 9
4 Tissue Engineered – Skin Substitute Procedures, France 11
4.1 Tissue Engineered – Skin Substitute Procedures, France, 2010-2017 11
4.2 Tissue Engineered – Skin Substitute Procedures, France, 2017-2024 13
4.2.1 Biologic Skin Substitute Procedures, France, 2010-2017 15
4.2.2 Biologic Skin Substitute Procedures, France, 2017-2024 17
5 Tissue Engineered – Skin Substitute Procedures, Germany 19
5.1 Tissue Engineered – Skin Substitute Procedures, Germany, 2010-2017 19
5.2 Tissue Engineered – Skin Substitute Procedures, Germany, 2017-2024 21
5.2.1 Biologic Skin Substitute Procedures, Germany, 2010-2017 23
5.2.2 Biologic Skin Substitute Procedures, Germany, 2017-2024 25
6 Tissue Engineered – Skin Substitute Procedures, Italy 27
6.1 Tissue Engineered – Skin Substitute Procedures, Italy, 2010-2017 27
6.2 Tissue Engineered – Skin Substitute Procedures, Italy, 2017-2024 29
6.2.1 Biologic Skin Substitute Procedures, Italy, 2010-2017 31
6.2.2 Biologic Skin Substitute Procedures, Italy, 2017-2024 33
7 Tissue Engineered – Skin Substitute Procedures, Spain 35
7.1 Tissue Engineered – Skin Substitute Procedures, Spain, 2010-2017 35
7.2 Tissue Engineered – Skin Substitute Procedures, Spain, 2017-2024 37
7.2.1 Biologic Skin Substitute Procedures, Spain, 2010-2017 39
7.2.2 Biologic Skin Substitute Procedures, Spain, 2017-2024 41
8 Tissue Engineered – Skin Substitute Procedures, United Kingdom 43
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/2479018-eu5-tissue-engineered-skin-substitute-procedures-outlook-to-2024

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Refining Market Analysis 2017 (By Segment, Key Players and Applications) and Forecasts To 2021

Refining Market 2017 Share, Trend, Segmentation and Forecast to 2021

PUNE, INDIA, November 22, 2017 /EINPresswire.com/ — Summary
"Global Refining Industry Outlook to 2021 – Capacity and Capital Expenditure Forecasts with Details of All Operating and Planned Refineries" is a comprehensive report on the global crude oil refining industry. The report provides refinery details such as the refinery name, country, and refinery operator name, with in-depth coverage on crude distillation unit or, CDU capacity and other major unit capacities for all active and new build (announced, planned and stalled) refineries. The report also provides global and regional refinery capital expenditure outlook by key countries, year on year, till 2021. The report also provides comparison of key countries based on contribution to global as well as regional refining capacities. Further the report also offers recent developments and latest contracts awarded in the refining industry across different regions.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/921535-global-refining-industry-outlook-and-planned-refineries

Scope
– Updated information relating to all active and planned refineries
– Provides historical data from 2011 to 2016, forecast to 2021
– Information on refining, FCC, hydrocracking and coking capacities by refinery and country
– Provides operator information for all active and planned refineries
– Latest developments and contracts related to refineries across different regions globally

Reasons to buy
– Obtain the most up to date information available on all active and planned refineries globally
– Identify growth segments and opportunities in the industry
– Facilitate decision making on the basis of strong historical and forecast of refinery and unit capacity data
– Assess your competitor’s refining portfolio

Table of Content: Key Points
1 Table of Contents 2
1.1 List of Tables 10
1.2 List of Figures 40
2 Introduction 44
2.1 What is This Report About? 44
2.2 Market Definition 44
3 Global Refining Industry 45
3.1 Global Refining Industry, Overview of Refineries Data 45
3.2 Global Refining Industry, Planned Refining Facilities 57
3.3 Global Refining Industry, New Units and Capacity Expansions by Region 61
3.4 Global Refining Industry, Regional Comparisons 69
4 Africa Refining Industry 73
4.1 Africa Refining Industry, Overview of Refineries Data 73
4.2 Africa Refining Industry, Total Refining Capacity 73
4.3 Africa Refining Industry, Planned Refineries, Capacity Expansions and Capex by Country 83
4.4 Africa Refining Industry, New Units and Capacity Expansions by Countries 88
4.5 Refining Industry in Egypt 93
4.6 Refining Industry in Algeria 96
4.7 Refining Industry in Libya 98
4.8 Refining Industry in South Africa 99
4.9 Refining Industry in Nigeria 101
4.10 Refining Industry in Morocco 105
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/921535-global-refining-industry-outlook-and-planned-refineries

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Legal Marijuana Sales Global Market 2017: Key Players – Aphria , Aurora Cannabis Inc. , Medicine Man, mCig Inc

Global Legal Marijuana Sales Market

PUNE, MAHARASHTRA, INDIA, November 22, 2017 /EINPresswire.com/ —

SUMMARY

WiseGuyReports published new report, title “Global Legal Marijuana Sales Market Report”

WiseGuyReports has announced the addition of “Report Full Title” that provides the market survey of “report keyword. The research report presents a comprehensive overview of market and growth trends of this industry in the coming years.

Firstly, the report provides a basic overview of the industry including its definition, applications and manufacturing technology. Then, the report explores the international and regional major industry players in detail. In this part, the report presents the company profile, product specifications, capacity, production value, and 2012-2017 market shares for each company.
Extensive primary research includes detailed analysis of properties and quantitative aspects of various industrial experts, to gain key insights into market and industrial performance for key opinion leaders.
Geographically, this report split global into several key Regions, with sales (Kg), revenue (Million USD), market share and growth rate of Legal Marijuana for these regions, from 2012 to 2022 (forecast), covering

United States
China
Europe
Japan
Southeast Asia
India

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/1387614-global-legal-marijuana-sales-market-report-2017

“Report keyword” factual study report gives an all-inclusive examination of the “report keyword” market and its key assessment and predictions for the forecast period. The report considers the current conditions of the market and joins a discussion on the market drivers, restraints, opportunities and challenges as well as the trends. It also studies and furnishes the summaries of the important manufacturers in the market, which includes their product/service offering, their financial overview and the strategies followed, with their competitors.

The report identifies the strengths, weaknesses, opportunities and threats each key player faces.

This report plays a key role in understanding market segments, based on types, applications, and regions. It covers the industry Supply/Value Chain Analysis which explains the processes from the method of manufacture to distribution and end -use as well as it explains the technical skills required which are unique to the industry. Raw material costs, labor costs, the production expenditure of product, equipment costs and other expenses, which impact the growth of a particular player, thus influencing the development of the market, are integrated in the report.

Legal Marijuana market competition by top manufacturers/players, with Legal Marijuana sales volume, Price (USD/g), revenue (Million USD) and market share for each manufacturer/player; the top players including

Medicine Man
Canopy Growth
Aphria
Aurora Cannabis Inc.
mCig Inc

Table of Contents

1 Global Legal Marijuana Sales Market Report 2017
2 Global Legal Marijuana Competition by Players/Suppliers, Type and Application
3 United States Legal Marijuana (Volume, Value and Sales Price)
4 China Legal Marijuana (Volume, Value and Sales Price)
5 Europe Legal Marijuana (Volume, Value and Sales Price)
6 Japan Legal Marijuana (Volume, Value and Sales Price)
7 Southeast Asia Legal Marijuana (Volume, Value and Sales Price)
8 India Legal Marijuana (Volume, Value and Sales Price)
9 Global Legal Marijuana Players/Suppliers Profiles and Sales Data
10 Legal Marijuana Maufacturing Cost Analysis
11 Industrial Chain, Sourcing Strategy and Downstream Buyers
12 Marketing Strategy Analysis, Distributors/Traders
13 Market Effect Factors Analysis
14 Global Legal Marijuana Market Forecast (2017-2022)
15 Research Findings and Conclusion
16 Appendix

..CONTINUED

About Us

Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Reinsurance in Lithuania Market Analysis 2017 (By Segment, Key Players and Applications) and Forecasts To 2021

Reinsurance in Lithuania Market 2017 – Opportunity, Driving Trends and deep study.

PUNE, INDIA, November 22, 2017 /EINPresswire.com/ — Synopsis
'Reinsurance in Lithuania Key Trends and Opportunities to 2021' report provides detailed analysis of the market trends, drivers and challenges in the Lithuanian reinsurance segment.

It provides values for key performance indicators such as written premium, reinsurance ceded and reinsurance accepted during the review period (2012–2016) and forecast period (2016–2021).

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/2529462-reinsurance-in-lithuania-key-trends-and-opportunities-to-2021

The report also analyzes information pertaining to the competitive landscape in the country, gives a comprehensive overview of the Lithuanian economy and demographics, and provides detailed analysis of natural hazards and their impact on the Lithuanian insurance industry.

The report brings together research, modeling and analysis expertise to enable reinsurers to identify segment dynamics and competitive advantages, and access profiles of reinsurers operating in the country.

Summary
'Reinsurance in Lithuania Key Trends and Opportunities to 2021' report provides in-depth market analysis, information and insights into the Lithuanian reinsurance segment, including:

• An outlook of the Lithuanian reinsurance segment
• A comprehensive overview of the Lithuanian economy and demographics
• Detailed analysis of natural hazards and their impact on the Lithuanian insurance industry
• The competitive landscape in the Lithuanian reinsurance segment

Scope
This report provides a comprehensive analysis of the reinsurance segment in Lithuania:
• It provides historical values for the Lithuanian reinsurance segment for the report’s 2012–2016 review period, and projected figures for the 2016–2021 forecast period.
• It offers a detailed analysis of the key categories in the Lithuanian reinsurance segment, and market forecasts to 2021.
• It provides a detailed analysis of the reinsurance ceded from various direct insurance segments in Lithuania, and the reinsurance segment's growth prospects.
• It analyzes various natural hazards and their impact on the Lithuania insurance industry

Reasons to Buy
• Make strategic business decisions using in-depth historic and forecast market data related to the Lithuanian reinsurance segment, and each category within it.
• Understand the demand-side dynamics, key market trends and growth opportunities in the Lithuanian reinsurance segment.
• Identify growth opportunities and market dynamics in key product categories.
• Gain insights into key regulations governing the Lithuanian insurance industry, and their impact on companies and the industry's future.

Key Highlights
• On May 29, 2017, the EC authorized the signing of a bilateral agreement regarding prudential measures of insurance and reinsurance between the US and the EU, which was agreed on January 13, 2017.
• On March 31, 2017, the Insurance Block Exemption Regulation (Regulation 267/2010) (IBER) expired. The IBER exempts insurers and reinsurers from certain applicable competition rules, subject to conditions and agreements between companies.
• Solvency II came into effect on January 1, 2016. It is based on three pillars: risk-based quantitative requirements; governance and supervision; and disclosure and transparency.

Table of Content: Key Points
1 Key Facts and Highlights
2 Executive Summary
3 Economy and Demographics
4 Reinsurance outlook
4.1 Reinsurance by Premium Ceded
5 Natural and Man-Made Hazards
5.1 Flooding
5.2 Droughts
5.3 Landslide
5.4 Exposure
6 Competitive Landscape
7 Definition and Methodology
7.1 Definitions
7.2 Methodology
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/2529462-reinsurance-in-lithuania-key-trends-and-opportunities-to-2021

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire